CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

3D-Bioprinted Platform For Comprehensive Cell Analysis

3D-Bioprinted Platform For...

Significance of Bioanalytical Services

Significance of Bioanalytical Services

Enhancing Bioanalytical Workflows with Latest Technology

Enhancing Bioanalytical Workflows...

How Remote Monitoring can Improve Healthcare Delivery?

How Remote Monitoring can Improve...

What You Should Know About Bioanalytical Method Validation

What You Should Know About...

What are Some Popular Applications of Analytical Testing Techniques?

What are Some Popular Applications of...

The Role of Technology in Transforming Bioanalysis

The Role of Technology in...

Forbion Announces its New General Partner

Forbion Announces its New General...

3D-Bioprinted Platform For Comprehensive Cell Analysis

3D-Bioprinted Platform For...

Significance of Bioanalytical Services

Significance of Bioanalytical Services

Enhancing Bioanalytical Workflows with Latest Technology

Enhancing Bioanalytical Workflows...

How Remote Monitoring can Improve Healthcare Delivery?

How Remote Monitoring can Improve...

What You Should Know About Bioanalytical Method Validation

What You Should Know About...

What are Some Popular Applications of Analytical Testing Techniques?

What are Some Popular Applications of...

The Role of Technology in Transforming Bioanalysis

The Role of Technology in...

Forbion Announces its New General Partner

Forbion Announces its New General...

Bioanalytical Challenges of Antibody Drug Conjugates

Life Sciences Review | Thursday, March 18, 2021
Tweet

The bioanalysis of antibody-drug conjugates (ADCs) is essential for understanding pharmaceutical drug safety and efficiency. 


FREMONT, CA: Bioanalysis of antibody-drug conjugates (ADCs) is essential for evaluating the safety and efficacy of this rapidly increasing class of pharmaceuticals. Here are some of the reasons that make ADC bioanalysis so complicated. ADCs are made up of cytotoxic small molecule drugs that have been chemically linked to an antibody. The antibody recognizes a tumor-associated antigen that is only expressed in a limited number of normal cells.


Cleavable chemical linkers are developed to remain stable in the circulation and release the cytotoxic drug (also known as the "payload") when some aspects inside the target cell are triggered. A refined pH range, high glutathione concentrations, or proteolytic cleavage are examples of "releasing" triggers. The resulting free drug will destroy the target cell directly and then leave the cell, causing "bystander killing" of nearby cells.


Non-cleavable linkers, on the other hand, lack an apparent proteolytic cleavage site, allowing the cytotoxic payload to remain inside the cell. ADCs with non-cleavable linkers activate the cytotoxic payload rather than the linker when the antibody is degraded. 


ADCs are made up of several different components. 


In some cases, the cytotoxic drug may efflux from the cell and be metabolized into smaller segments with other anticancer activity to the parent drug. In general, intact ADCs, free drug molecules, conjugated antibody, and complete antibody are all measured in ADC bioanalysis. This diverse group of organisms poses unique bioanalytical challenges, necessitating identifying techniques appropriate for various stages of research and development.


ADC components are heterogenous


One of the critical causes of variability is the number of drugs attached to every antibody. The drug-to-antibody ratio (DAR), described as the average number of drugs conjugated to each antibody (usually between 0 and 8), influences stability, antigen binding, and, eventually, ADC potency. A lower DAR can minimize ADC potency, whereas a high drug loading can boost clearance, increase the risk of accumulation, and cause the toxic payload to be released prematurely into the circulation.


The conjugation area at which the payload is conjugated to the antibody is another source of heterogeneity. In the meantime, efforts are being made to generate more homogeneous ADCs by monitoring the site and number of drugs conjugated to the antibody, but analytical procedures must account for this variability.


Weekly Brief

loading
Top 10 Bioanalytical Service Companies in Europe - 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/bioanalytical-challenges-of-antibody-drug-conjugates-nwid-293.html